Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

Author
Laud, Peter J.
Paz-Ares, Luis
Patel, Nikunj
Shire, Norah
Jiang, Haiyi
Goldman, Jonathan W.
Garassino, Marina Chiara
Chen, Yuanbin
ÖZGÜROĞLU, Mustafa
Dvorkin, Mikhail
Trukhin, Dmytro
Statsenko, Galina
Hotta, Katsuyuki
Ji, Jun Ho
Hochmair, Maximilian J.
Voitko, Oleksandr
Havel, Libor
Poltoratskiy, Artem
Losonczy, Gyorgy
Reinmuth, Niels
Metadata
Show full item record
Abstract
Objectives: In the phase III CASPIAN study, first-line durvalumab plus etoposide in combination with either cisplatin or carboplatin (EP) significantly improved overall survival (primary endpoint) versus EP alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) at the interim analysis. Here we report patient-reported outcomes (PROs).
URI
http://hdl.handle.net/20.500.12627/154252
https://doi.org/10.1016/j.lungcan.2020.09.003
Collections